Contact Us
Drug Search Results
More Filters [+]

Aclidinium

Alternative Names: aclidinium, aclidinium bromide, genuair, tudorza pressair, duaklir pressair
Latest Update: 2024-12-13
Latest Update Note: Clinical Trial Update

Product Description

Aclidinium is used as a long term treatment to prevent wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD, a group of diseases that affect the lungs and airways) such as chronic bronchitis (swelling of the air passages that lead to the lungs) and emphysema (damage to air sacs in the lungs). Aclidinium is in a class of medications called bronchodilators. It works by relaxing and opening the air passages to the lungs to make breathing easier.

Mechanisms of Action: LAM Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States

Approved Indications: Headache | Spasm | Nasopharyngitis | Pharyngitis | Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema | Spasm | Asthma | Chronic Obstructive Pulmonary Disease

Known Adverse Events: Headache | Nasopharyngitis | Pharyngitis | Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema | Respiratory Tract Infections

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aclidinium

Countries in Clinic: China, India, Philippines, Taiwan, Vietnam

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
AVANT

P3

Completed

Chronic Obstructive Pulmonary Disease

2022-04-14

92%

Recent News Events

Date

Type

Title

01/05/2024

News Article

 Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

09/21/2023

News Article

 Bronchial Spasms Treatment Market Size, Growth 2023-2031

02/20/2023

News Article

 Genetic Chronic Obstructive Pulmonary Disease (COPD) Market to Surpass US$ 720.5 Million by 2030, Says Coherent Market Insights (CMI)

10/25/2022

News Article

 Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions